메뉴 건너뛰기




Volumn 118, Issue 9, 2012, Pages 2507-2515

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid

Author keywords

arsenic trioxide; autologous transplantation; bortezomib; melphalan; myeloma

Indexed keywords

ACICLOVIR; ARSENIC TRIOXIDE; ASCORBIC ACID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; LENALIDOMIDE; LEVOFLOXACIN; MELPHALAN; THALIDOMIDE; VINCRISTINE;

EID: 84860219808     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26517     Document Type: Article
Times cited : (39)

References (32)
  • 2
    • 77249120064 scopus 로고    scopus 로고
    • Treatment of multiple myeloma: A comprehensive review
    • Kyle RA, Rajkumar SV,. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma. 2009; 9: 278-288.
    • (2009) Clin Lymphoma Myeloma. , vol.9 , pp. 278-288
    • Kyle, R.A.1    Rajkumar, S.V.2
  • 3
    • 8944220233 scopus 로고    scopus 로고
    • A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome
    • Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996; 335: 91-97.
    • (1996) N Engl J Med. , vol.335 , pp. 91-97
    • Attal, M.1    Harousseau, J.L.2    Stoppa, A.M.3
  • 4
    • 0037739753 scopus 로고    scopus 로고
    • High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
    • Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 1875-1883.
    • (2003) N Engl J Med. , vol.348 , pp. 1875-1883
    • Child, J.A.1    Morgan, G.J.2    Davies, F.E.3
  • 5
    • 79953718494 scopus 로고    scopus 로고
    • Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma
    • Kazmi SM, Saliba RM, Donato M, et al. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant. 2011; 46: 510-515.
    • (2011) Bone Marrow Transplant. , vol.46 , pp. 510-515
    • Kazmi, S.M.1    Saliba, R.M.2    Donato, M.3
  • 6
    • 2642517876 scopus 로고    scopus 로고
    • Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma
    • Anagnostopoulos A, Aleman A, Ayers G, et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 2004; 100: 2607-2612.
    • (2004) Cancer. , vol.100 , pp. 2607-2612
    • Anagnostopoulos, A.1    Aleman, A.2    Ayers, G.3
  • 7
    • 0036464598 scopus 로고    scopus 로고
    • 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
    • 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002; 99: 731-735.
    • (2002) Blood. , vol.99 , pp. 731-735
    • Moreau, P.1    Facon, T.2    Attal, M.3
  • 8
    • 34247177131 scopus 로고    scopus 로고
    • Results of a retrospective single institution analysis of targeted skeletal radiotherapy with Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes
    • Christoforidou AV, Saliba RM, Williams P, et al. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant. 2007; 13: 543-549.
    • (2007) Biol Blood Marrow Transplant. , vol.13 , pp. 543-549
    • Christoforidou, A.V.1    Saliba, R.M.2    Williams, P.3
  • 9
    • 0037973279 scopus 로고    scopus 로고
    • A phase 2 study of bortezomib in relapsed, refractory myeloma
    • Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348: 2609-2617.
    • (2003) N Engl J Med. , vol.348 , pp. 2609-2617
    • Richardson, P.G.1    Barlogie, B.2    Berenson, J.3
  • 10
    • 20444433230 scopus 로고    scopus 로고
    • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
    • Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352: 2487-2498.
    • (2005) N Engl J Med. , vol.352 , pp. 2487-2498
    • Richardson, P.G.1    Sonneveld, P.2    Schuster, M.W.3
  • 11
    • 73349115580 scopus 로고    scopus 로고
    • Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma
    • Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009; 27: 5713-5719.
    • (2009) J Clin Oncol. , vol.27 , pp. 5713-5719
    • Richardson, P.G.1    Weller, E.2    Jagannath, S.3
  • 12
    • 0037342894 scopus 로고    scopus 로고
    • The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents
    • Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003; 9: 1136-1144.
    • (2003) Clin Cancer Res. , vol.9 , pp. 1136-1144
    • Ma, M.H.1    Yang, H.H.2    Parker, K.3
  • 13
    • 0037443551 scopus 로고    scopus 로고
    • The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications
    • Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003; 101: 2377-2380.
    • (2003) Blood. , vol.101 , pp. 2377-2380
    • Mitsiades, N.1    Mitsiades, C.S.2    Richardson, P.G.3
  • 14
    • 50449086728 scopus 로고    scopus 로고
    • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    • San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359: 906-917.
    • (2008) N Engl J Med. , vol.359 , pp. 906-917
    • San Miguel, J.F.1    Schlag, R.2    Khuageva, N.K.3
  • 15
    • 74949119502 scopus 로고    scopus 로고
    • Intergroupe Francophone du Myelome (IFM). Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the Intergroupe Francophone du Myelome (IFM)
    • .
    • Roussel M, Moreau P, Huynh A, et al. Intergroupe Francophone du Myelome (IFM). Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood. 2010; 15: 32-37.
    • (2010) Blood. , vol.15 , pp. 32-37
    • Roussel, M.1    Moreau, P.2    Huynh, A.3
  • 16
    • 56549083786 scopus 로고    scopus 로고
    • Arsenic trioxide with ascorbic acid and high-dose melphalan: Results of a phase II randomized trial
    • Qazilbash MH, Saliba RM, Nieto Y, et al. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008; 14: 1401-1407.
    • (2008) Biol Blood Marrow Transplant. , vol.14 , pp. 1401-1407
    • Qazilbash, M.H.1    Saliba, R.M.2    Nieto, Y.3
  • 17
    • 84988241358 scopus 로고    scopus 로고
    • International uniform response criteria for multiple myeloma
    • Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473.
    • (2006) Leukemia. , vol.20 , pp. 1467-1473
    • Durie, B.G.1    Harousseau, J.L.2    Miguel, J.S.3
  • 18
    • 77649151227 scopus 로고    scopus 로고
    • In the age of novel therapies, what defines high-risk multiple myeloma?
    • Badros AZ,. In the age of novel therapies, what defines high-risk multiple myeloma? J Natl Compr Canc Netw. 2010; 8 (suppl 1): S28-S34.
    • (2010) J Natl Compr Canc Netw. , vol.8 , Issue.SUPPL. 1
    • Badros, A.Z.1
  • 20
    • 0002386913 scopus 로고
    • On the interpretation of x2 from contingency tables, and the calculation of P
    • Fischer R,. On the interpretation of x2 from contingency tables, and the calculation of P. J R Stat Soc. 1922; 85: 87-94.
    • (1922) J R Stat Soc. , vol.85 , pp. 87-94
    • Fischer, R.1
  • 22
    • 33845382806 scopus 로고
    • Non-parametric estimation from incomplete observation
    • Kaplan EL, Meier P,. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457-481.
    • (1958) J Am Stat Assoc. , vol.53 , pp. 457-481
    • Kaplan, E.L.1    Meier, P.2
  • 23
    • 0013886333 scopus 로고
    • Evaluation of survival data and 2 new rank order statistics arising in its consideration
    • Mantel N,. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163-170.
    • (1966) Cancer Chemother Rep. , vol.50 , pp. 163-170
    • Mantel, N.1
  • 25
    • 0000120766 scopus 로고
    • Estimating the dimension of a model
    • Schwarz GE,. Estimating the dimension of a model. Ann Stat. 1978; 6: 461-464.
    • (1978) Ann Stat. , vol.6 , pp. 461-464
    • Schwarz, G.E.1
  • 26
    • 79956039754 scopus 로고    scopus 로고
    • Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2
    • Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011; 117: 4696-4700.
    • (2011) Blood. , vol.117 , pp. 4696-4700
    • Munshi, N.C.1    Anderson, K.C.2    Bergsagel, P.L.3
  • 29
    • 77958065790 scopus 로고    scopus 로고
    • A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: A dose- and schedule-finding study
    • Lonial S, Kaufman J, Tighiouart M, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res. 2010; 16: 5079-5086.
    • (2010) Clin Cancer Res. , vol.16 , pp. 5079-5086
    • Lonial, S.1    Kaufman, J.2    Tighiouart, M.3
  • 30
    • 33644510445 scopus 로고    scopus 로고
    • Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma
    • Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006; 106: 1084-1089.
    • (2006) Cancer. , vol.106 , pp. 1084-1089
    • Qazilbash, M.H.1    Saliba, R.2    De Lima, M.3
  • 31
    • 70450189443 scopus 로고    scopus 로고
    • Commentary on Perrone, et al. "vitamin C: Not for breakfast anymore. if you have myeloma."
    • Harvey RD, Nettles J, Wang B, Sun SY, Lonial S,. Commentary on Perrone, et al. "vitamin C: not for breakfast anymore. if you have myeloma." Leukemia. 2009; 23: 1939-1940.
    • (2009) Leukemia. , vol.23 , pp. 1939-1940
    • Harvey, R.D.1    Nettles, J.2    Wang, B.3    Sun, S.Y.4    Lonial, S.5
  • 32
    • 70349303770 scopus 로고    scopus 로고
    • Ascorbic acid inhibits antitumor activity of bortezomib in vivo
    • Perrone G, Hideshima T, Ikeda H, et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia. 2009; 23: 1679-1686.
    • (2009) Leukemia. , vol.23 , pp. 1679-1686
    • Perrone, G.1    Hideshima, T.2    Ikeda, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.